- Belgrade '18
- Vienna '18
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: K.Solomon USA
Co Author(s): H. Sandoval
Back to previous
To evaluate the results of the iStent implanted at time of routine cataract surgery in patients diagnosed with chronic open angle glaucoma.
Carolina Eyecare Physcians, Charleston, SC, USA
Retrospective chart review of patient who underwent uneventful phacoemulsification and iStent Trabecular Micro Bypass (Glaukos Corporation) implantation between August 1, 2012 and January 30, 2013. All patients had one iStent implanted. Preoperative and at least 3-week postoperative intraocular pressure (IOP), number of medications used, and iStent intra and postoperative complications were evaluated. Patients taking combination drops (i.e. Cosopt) were included as using 2 medications.
A total of 33 eyes of 21 patients had complete information and were analyzed. Mean age was 72.3 ḟ7.0 years. Forty-eight percent were females. Mean preoperative IOP was 16.9 ±5.0 mmHg; 86% (18), 9% (2), and 5% (1) were using 1, 2, and 3 medications, respectively. Mean IOP on day 1 after surgery was 18.8 ḟ6.8 mmHg and 16.1 ḟ5.1 mmHg on postoperative day 21. Three eyes of 3 patients who had unilateral implantation of the iStent were still using anti-glaucoma drops. When excluding these 3 eyes, the mean IOP was 15.8 ḟ5.5 mmHg at the 3 weeks postoperative visit. Patients using 2 and 3 medications prior to surgery were not using any medication postoperatively. No intraoperative or postoperative complications were seen.
The use of iStent reduced the IOP to baseline levels without using any anti-glaucoma medication. iStent seems to be a safe alternative to patients with chronic open glaucoma undergoing cataract surgery.
... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented